Insider Selling: LivaNova PLC (LIVN) Director Sells $84,660.00 in Stock

LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $84.66, for a total transaction of $84,660.00. The sale was disclosed in a filing with the SEC, which is available through this link.

Daniel Jeffrey Moore also recently made the following trade(s):

  • On Monday, April 16th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $86.24, for a total transaction of $86,240.00.
  • On Thursday, March 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $88.31, for a total transaction of $88,310.00.

Shares of NASDAQ:LIVN traded up $0.63 during mid-day trading on Friday, reaching $83.86. The stock had a trading volume of 263,600 shares, compared to its average volume of 485,506. The company has a market capitalization of $4.06 billion, a price-to-earnings ratio of 26.37, a P/E/G ratio of 2.64 and a beta of 0.77. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.85 and a quick ratio of 1.51. LivaNova PLC has a twelve month low of $54.67 and a twelve month high of $92.31.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 2nd. The company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $250.40 million for the quarter, compared to the consensus estimate of $245.18 million. LivaNova had a negative net margin of 1.99% and a positive return on equity of 8.38%. LivaNova’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same period last year, the company posted $0.67 EPS. equities research analysts expect that LivaNova PLC will post 3.18 earnings per share for the current year.

Several research analysts have recently issued reports on LIVN shares. ValuEngine raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd. Zacks Investment Research lowered shares of LivaNova from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $104.00 target price (up previously from $97.00) on shares of LivaNova in a research note on Wednesday, February 28th. BidaskClub raised shares of LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, January 26th. Finally, BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $81.43.

Large investors have recently made changes to their positions in the stock. LS Investment Advisors LLC raised its position in shares of LivaNova by 41.3% in the 4th quarter. LS Investment Advisors LLC now owns 4,957 shares of the company’s stock valued at $396,000 after acquiring an additional 1,450 shares during the period. Invictus RG raised its position in shares of LivaNova by 69.2% in the 4th quarter. Invictus RG now owns 9,302 shares of the company’s stock valued at $743,000 after acquiring an additional 3,805 shares during the period. Crossmark Global Holdings Inc. raised its position in shares of LivaNova by 88.6% in the 4th quarter. Crossmark Global Holdings Inc. now owns 7,090 shares of the company’s stock valued at $567,000 after acquiring an additional 3,330 shares during the period. Teacher Retirement System of Texas raised its position in shares of LivaNova by 321.0% in the 4th quarter. Teacher Retirement System of Texas now owns 14,239 shares of the company’s stock valued at $1,138,000 after acquiring an additional 10,857 shares during the period. Finally, BlackRock Inc. raised its position in shares of LivaNova by 3.2% in the 4th quarter. BlackRock Inc. now owns 4,796,615 shares of the company’s stock valued at $383,345,000 after acquiring an additional 149,678 shares during the period. Institutional investors and hedge funds own 86.12% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply